ALX Oncology Holdings Inc. (ALXO) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to the AOX Syncology second quarter 2025 financial results conference call and webcast. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone requires operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Jason Letman, you may begin. Thanks, everyone, and welcome to our Q2 2025 results. I appreciate everybody spending some time this afternoon with us and looking forward to this update. On slide two, before we start our presentation as housekeeping, here are our forward-looking statements for your review. So, in terms of slide three, this is the agenda and plan for today. We're going to be providing an update on our key accomplishments in the second quarter of 2025. Most notably, we are very excited to share with you new data from our analysis of our Aspen 6 trial that showed CD47 expression as a key predictive biomarker for increasing clinical response with the 4-percept. So our goals for today are most importantly to share this new data with you all, then give you a sense of how this data now impacts our development strategy for Evo, then provide a quick update on our novel EGFR-targeted ADC, ALX 2004, which is set to enter the clinic imminently, as well as share revised guidance on our financials and cash position. So in terms of the agenda, our CMO, Alan, will first present these top-line results and also provide an update of our clinical programs with Evo. Harish will then conclude by an update on our cash runway as well as our near-term key milestones. And last, we'll open it up to you all for a Q&A. On the next slid...